Scleroderma Research Study

The purpose of the study is to research a new treatment for Scleroderma related lung disease (ILD).

As part of the study, you will receive physical exams, High Resolution CT (HRCT), Pulmonary Function Testing (PFTs) and safety lab results.

To qualify for study participation, you must be:
1. Over 18 years old
2. Diagnosed with Scleroderma (SSc) within the last 7 years
3. Diagnosed with Interstitial Lung Disease (ILD)
4. No smoking in the last 6 months
5. Not pregnant or breastfeeding

For other inclusion criteria, please contact the study team.

For more information, please contact Mallary Crow Adams at 303-724-8403 or MallaryCrowAdams@ucdenver.edu.

“Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma related interstitial lung disease”